InvestorsHub Logo
Followers 13
Posts 559
Boards Moderated 0
Alias Born 12/31/2012

Re: None

Sunday, 03/21/2021 3:42:06 PM

Sunday, March 21, 2021 3:42:06 PM

Post# of 1221
Huge endorsement & derisking event for NDRA & their TAEUS technology.
Hepion Pharma commits to using TAEUS in their critical Phase 2b NASH study even though TAEUS has not received FDA 510k Clearance yet??? Unprecedented IMO. This is strong evidence of just large the market for TAEUS will be...

Consider the opinion of someone who is not long NDRA but has done his due diligence. In fact, he is the CEO of another company. And he is bullish on TAEUS:

"Hepion Pharma is excited to incorporate ENDRA's technology into screening for our Phase 2b study of CRV431, which targets non-alcoholic steatohepatitis (NASH) and other liver diseases," said Hepion's CEO Dr. Robert Foster."

"... there is enormous potential value in capturing data on the degree of hepatic steatosis and other biomarkers to refine our understanding of systemic variables associated with NAFLD-NASH. We believe ENDRA's TAEUS system is uniquely designed to accomplish this task for us."

http://investors.endrainc.com/prviewer/release_only/id/4662746
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NDRA News